- Home
- AUPH vs APLT Comparison
AUPH vs APLT Comparison
Compare AUPH & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUPH
- APLT
- Stock Information
- Founded
- AUPH 1993
- APLT 2016
- Country
- AUPH Canada
- APLT United States
- Employees
- AUPH N/A
- APLT N/A
- Industry
- AUPH Biotechnology: Pharmaceutical Preparations
- APLT Biotechnology: Pharmaceutical Preparations
- Sector
- AUPH Health Care
- APLT Health Care
- Exchange
- AUPH Nasdaq
- APLT Nasdaq
- Market Cap
- AUPH 1.1B
- APLT 44.0M
- IPO Year
- AUPH 1999
- APLT 2019
- Fundamental
- Price
- AUPH $8.86
- APLT $0.41
- Analyst Decision
- AUPH Strong Buy
- APLT Buy
- Analyst Count
- AUPH 2
- APLT 7
- Target Price
- AUPH $11.50
- APLT $6.10
- AVG Volume (30 Days)
- AUPH 1.9M
- APLT 2.6M
- Earning Date
- AUPH 07-31-2025
- APLT 08-06-2025
- Dividend Yield
- AUPH N/A
- APLT N/A
- EPS Growth
- AUPH N/A
- APLT N/A
- EPS
- AUPH 0.27
- APLT N/A
- Revenue
- AUPH $247,295,000.00
- APLT $265,000.00
- Revenue This Year
- AUPH $12.15
- APLT $1,768.13
- Revenue Next Year
- AUPH $18.31
- APLT $292.85
- P/E Ratio
- AUPH $33.04
- APLT N/A
- Revenue Growth
- AUPH 29.20
- APLT N/A
- 52 Week Low
- AUPH $5.20
- APLT $0.30
- 52 Week High
- AUPH $10.67
- APLT $10.62
- Technical
- Relative Strength Index (RSI)
- AUPH 64.10
- APLT 58.87
- Support Level
- AUPH $7.36
- APLT $0.32
- Resistance Level
- AUPH $9.10
- APLT $0.36
- Average True Range (ATR)
- AUPH 0.44
- APLT 0.04
- MACD
- AUPH 0.10
- APLT 0.01
- Stochastic Oscillator
- AUPH 89.53
- APLT 94.92
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.